1997
Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine
Al-Abed Y, Bucala R. Efficient Scavenging of Fatty Acid Oxidation Products by Aminoguanidine. Chemical Research In Toxicology 1997, 10: 875-879. PMID: 9282836, DOI: 10.1021/tx970035l.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein levelsAdvanced glycation end productsGlycation end productsMechanism of actionVascular wall componentsLipoprotein levelsLipoprotein metabolismOxidative stressPharmacological inhibitorsFatty acid oxidation productsHuman subjectsToxic effectsAminoguanidineOxidative damageNormal pathwayReactive aldehydesRecent studiesPotential interactionsDamaging effectsVivoTissue constituentsEnd productsAtherogenesisLipid oxidationMalondialdehyde
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease